Fig. 5
[125I]sNEP-scFc-scFv8D3 in the brain, blood and peripheral organs post tracer dose 0.05 mg/kg body weight/0.3 nmol/kg body weight administrated intravenously in the tail vein in 7–8-month-old tg-ArcSwe mice. A Significantly higher brain uptake of [125I]sNEP-scFc-scFv8D3 compared to [125I]sNEP at 2 h post-injection. The concentration of the radioactivity detected in the tissue is presented as percent of injected dose per gramme tissue (%ID/g). B Significantly higher uptake of [125I]sNEP-scFc-scFv8D3 in the hippocampus at 2 h post-injection compared to other brain regions. A trend towards a higher retention (#) in the hippocampus detected 72 h post-injection. C Aβ immunostaining of sagittal brain sections prepared from brains isolated at 72 h post-[125I]-sNEP-scFc-scFv8D3 administration to tg-ArcSwe mice. Boxed areas show Aβ immunostaining (red) and DAPI (blue) in the (i) cortex, (ii) ventral striatum and (iii) hippocampus. D Significantly higher amounts of [125I]sNEP-scFc-scFv8D3 in blood pellet compared to plasma 2 h post-injection. E Biodistribution of [.125I]sNEP-scFc-scFv8D3 in peripheral organs of tg-ArcSwe mice, at 2, 6 and 72 h post-injection. Results presented as mean ± SD. Unpaired t-test or one-way ANOVA with Bonferroni’s multiple comparison test were applied (n = 3/sNEP-scFc-scFv8D3; n = 5/sNEP) (p > 0.05 = ns; p ≤ 0.05 = *; p ≤ 0.01 = **; p ≤ 0.001 = ***)